Drugs / Dalzanemdor
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03787758 | Feb → Oct 2019 | Huntington disease | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03844906 | Dec 2018 → Mar 2019 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03770780 | Nov 2018 → Mar 2019 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03771586 | Sep → Dec 2018 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05619692 | Nov 2022 → Jun 2024 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05318937 | Jun 2022 → Jan 2024 | Parkinson disease, cognitive disorder | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05358821 | May 2022 → Feb 2024 | Huntington disease | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05107128 | Jan 2022 → Sep 2024 | Huntington disease | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04602624 | Dec 2020 → Sep 2021 | Alzheimer disease | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04476017 | Jul 2020 → Mar 2022 | Parkinson disease, cognitive disorder | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05655520 | Dec 2022 → Jan 2025 | Huntington disease | Supernus Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalzanemdor | “Dalzanemdor (SAGE-718) is a novel, investigational NMDAR PAM” PMID 38988035 ↗ Jul 2024 |
| Known as | SAGE-718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05318937 ↗ |
| Modality | Small molecule | — CHEMBL5095095 ↗ |
| Route | Oral | “single, oral dose of SAGE-718” NCT03771586 ↗ |